167 related articles for article (PubMed ID: 26906432)
21. Genetic predisposition for nonmedullary thyroid cancer.
Nagy R; Ringel MD
Horm Cancer; 2015 Feb; 6(1):13-20. PubMed ID: 25338077
[TBL] [Abstract][Full Text] [Related]
22. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
23. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
24. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
25. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
26. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.
Lesueur F; Stark M; Tocco T; Ayadi H; Delisle MJ; Goldgar DE; Schlumberger M; Romeo G; Canzian F
J Clin Endocrinol Metab; 1999 Jun; 84(6):2157-62. PubMed ID: 10372725
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
28. The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds.
de Mello LEB; Araujo AN; Alves CX; de Paiva FJP; Brandão-Neto J; Cerutti JM
Clin Endocrinol (Oxf); 2017 Jul; 87(1):113-114. PubMed ID: 28418605
[No Abstract] [Full Text] [Related]
29. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Simeone P; Alberti S
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27418631
[No Abstract] [Full Text] [Related]
30. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
31. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
[TBL] [Abstract][Full Text] [Related]
32. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
33. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Carvajal-Carmona LG; Tomlinson I; Sahasrabudhe R
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27154966
[No Abstract] [Full Text] [Related]
34. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
[TBL] [Abstract][Full Text] [Related]
36. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
37. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
38. Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing.
Tous C; Muñoz-Redondo C; Bravo-Gil N; Gavilan A; Fernández RM; Antiñolo J; Navarro-González E; Antiñolo G; Borrego S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175550
[TBL] [Abstract][Full Text] [Related]
39. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
[TBL] [Abstract][Full Text] [Related]
40. Familial non-medullary thyroid carcinoma: an update.
Nosé V
Endocr Pathol; 2008; 19(4):226-40. PubMed ID: 18931957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]